APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
+23.63%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$4.28B
AUM Growth
+$4.28B
(-6.9%)
Cap. Flow
-$594M
Cap. Flow
% of AUM
-13.88%
Top 10 Holdings %
Top 10 Hldgs %
42.06%
Holding
115
New
18
Increased
32
Reduced
19
Closed
30
Top Buys
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$125M |
| 2 |
Universal Health Services
UHS
|
$116M |
| 3 |
Surgery Partners
SGRY
|
$79.2M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$65.2M |
| 5 |
Prothena Corp
PRTA
|
$59.4M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$289M |
| 2 |
Biogen
BIIB
|
$160M |
| 3 |
SPDR S&P Biotech ETF
XBI
|
$117M |
| 4 |
Humana
HUM
|
$103M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$98.4M |
Sector Composition
| 1 | Healthcare | 99.55% |
| 2 | Financials | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Revolution Medicines
RVMD
$7.52B
| $59M | 1.28% |
2,475,000
+153,800
| +7% | +$3.66M |
|
|
KRTX
27
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $58.8M | 1.27% |
299,000
-132,800
| -31% | -$26.1M |
|
28
Arrowhead Research
ARWR
$3.72B
| $55.8M | 1.21% |
1,375,000
+119,626
| +10% | +$4.85M |
|
29
Axsome Therapeutics
AXSM
$6.13B
| $51.7M | 1.12% |
670,000
-868,600
| -56% | -$67M |
|
|
30
Vertex Pharmaceuticals
VRTX
$102B
| $49.7M | 1.08% |
172,000
-340,800
| -66% | -$98.4M |
|
31
Legend Biotech
LEGN
$6.54B
| $48.4M | 1.05% |
+970,000
| New | +$48.4M |
|
32
Kezar Life Sciences
KZR
$28.6M
| $47.7M | 1.03% |
6,782,400
+1,368,000
| +25% | +$9.63M |
|
33
Pliant Therapeutics
PLRX
$105M
| $43.3M | 0.94% |
2,240,400
+259,300
| +13% | +$5.01M |
|
34
Ventyx Biosciences
VTYX
$183M
| $42.1M | 0.91% |
+1,285,000
| New | +$42.1M |
|
35
Icon
ICLR
$14B
| $41.8M | 0.9% |
+215,000
| New | +$41.8M |
|
36
Quest Diagnostics
DGX
$19.9B
| $40.4M | 0.87% |
+258,000
| New | +$40.4M |
|
37
Bio-Rad Laboratories Class A
BIO
$7.84B
| $38.8M | 0.84% |
92,200
-52,600
| -36% | -$22.1M |
|
|
BLU
38
DELISTED
BELLUS Health Inc.
BLU
| $37.8M | 0.82% |
4,599,998
+253,298
| +6% | +$2.08M |
|
39
Tenet Healthcare
THC
$16.4B
| $35M | 0.76% |
+717,300
| New | +$35M |
|
40
Karyopharm Therapeutics
KPTI
$60.4M
| $32.8M | 0.71% |
+9,633,911
| New | +$32.8M |
|
41
BioNTech
BNTX
$24.2B
| $32.4M | 0.7% |
+215,400
| New | +$32.4M |
|
|
VERV
42
DELISTED
Verve Therapeutics
VERV
| $30.3M | 0.66% |
1,565,000
+522,294
| +50% | +$10.1M |
|
43
Rocket Pharmaceuticals
RCKT
$355M
| $29.9M | 0.65% |
+1,527,087
| New | +$29.9M |
|
|
ITCI
44
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $26.7M | 0.58% |
504,000
-898,500
| -64% | -$47.5M |
|
45
Arcutis Biotherapeutics
ARQT
$1.86B
| $26M | 0.56% |
1,755,000
+960,500
| +121% | +$14.2M |
|
|
RXDX
46
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $22.4M | 0.49% |
+204,000
| New | +$22.4M |
|
47
Intellia Therapeutics
NTLA
$1.29B
| $22.3M | 0.48% |
638,200
-360,900
| -36% | -$12.6M |
|
48
Vir Biotechnology
VIR
$749M
| $21.5M | 0.47% |
+850,000
| New | +$21.5M |
|
49
Phathom Pharmaceuticals
PHAT
$832M
| $21.3M | 0.46% |
1,900,000
-6,800
| -0.4% | -$76.3K |
|
50
Biohaven
BHVN
$1.75B
| $20.7M | 0.45% |
+1,492,000
| New | +$20.7M |
|